Most Read Articles
Elvira Manzano, 28 Mar 2021
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
Jairia Dela Cruz, 31 Mar 2021
Patients with indications for oral anticoagulant (OAC) therapy may be better off with novel (N)OACs versus warfarin in terms of bone health, as the former can reduce the risk of developing fractures, according to a systematic review and meta-analysis.

Aspirin plus statin equates to greater reduction in liver cancer risk

6 days ago

Daily aspirin use already exhibits a protective signal against hepatocellular carcinoma (HCC), but a recent study reports that concomitant use of statin can lead to a greater risk reduction without increasing the incidence of oesophageal variceal haemorrhage (VH).

The study examined the effect of concurrent use of aspirin and statin on the incidence of HCC, as well as to identify if it posed a risk of VH. The analysis included a prospective cohort of 521 patients with liver cirrhosis.

Alone, aspirin use produced a reduction in the incidence of HCC both in the univariate (hazard ratio [HR], 0.348, 95 percent confidence interval [CI], 0.124–0.976; p=0.0448) and multivariate (HR, 0.266, 95 percent CI, 0.094–0.755; p=0.0129) models.

Interestingly, the risk of HCC further decreased when aspirin and statin were taken concomitantly (univariate model: HR, 0.15, 95 percent CI, 0.036–0.624; p=0.0090). This association remained statistically significant in the multivariable model (HR, 0.113, 95 percent CI, 0.026–0.483; p=0.0033).

In terms of safety, daily aspirin users were not at heightened risk of VH compared with nonusers.

The findings indicate a potential beneficial interaction between aspirin and statin in relation with HCC risk. More studies are needed to validate the present data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Mar 2021
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
Jairia Dela Cruz, 31 Mar 2021
Patients with indications for oral anticoagulant (OAC) therapy may be better off with novel (N)OACs versus warfarin in terms of bone health, as the former can reduce the risk of developing fractures, according to a systematic review and meta-analysis.